ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2026)

ARS Pharmaceuticals has disclosed Retained Earnings across 6 years of filings, most recently posting -$355.2 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$355.2 million, down 493462.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$355.2 million (down 493462.5% YoY), and the FY2025 annual result was $125000.0, up 100.1% from the prior year.
• Retained Earnings came in at -$355.2 million for Q1 2026 at ARS Pharmaceuticals, down from $125000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $407000.0 in Q4 2022 to a low of -$355.2 million in Q1 2026.
• The 5-year median for Retained Earnings is -$91.9 million (2023), against an average of -$103.0 million.
• Across the five-year window, Retained Earnings soared 158.06% in 2025 and tumbled 493462.5% in 2026, its largest moves.
• ARS Pharmaceuticals' Retained Earnings stood at $407000.0 in 2022, then slumped by 87.96% to $49000.0 in 2023, then slumped by 251742.86% to -$123.3 million in 2024, then jumped by 100.1% to $125000.0 in 2025, then sank by 284276.8% to -$355.2 million in 2026.
• The last three Retained Earnings figures came in at -$355.2 million (Q1 2026), $125000.0 (Q4 2025), and -$253.3 million (Q3 2025), per Business Quant data.